Senseonics (NYSE:SENS) announced that it made equity grants to new employees under its 2019 inducement plan. Germantown, Maryland–based Senseonics, which develops the Eversense family continuous glucose monitoring (CGM) systems, including the latest-generation Eversense E3 180-day CGM, made the equity grants in accordance with the NYSE American Company Guide Section 711(a). Get the full story at our […]
Senseonics
Senseonics wins CE mark approval for 180-day Eversense E3 CGM
Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system. Germantown, Maryland-based Senseonics offered its previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days). Europe already had a 180-day Senseonics CGM system available (Eversense XL), […]
Senseonics beats The Street in Q1 following Eversense E3 launch
Senseonics (NYSE:SENS) posted first-quarter results that topped the consensus revenue forecast on Wall Street. The Germantown, Maryland-based company posted profits of $86.7 million, or 19¢ per share, on sales of $2.5 million for the three months ended March 31, 2022, for a massive bottom-line gain from losses of $249.5 million this time last year despite a […]
Senseonics announces first Eversense E3 CGM implant in U.S.
Senseonics (NYSE:SENS) announced today that the first patient was implanted with its next-generation Eversense E3 continuous glucose monitor. Germantown, Maryland-based Senseonics, in partnership with Ascensia Diabetes Care, launched the Eversense E3 long-term implantable CGM system in the U.S. earlier this week. The system received FDA approval in February for use lasting up to six months (180 days), making […]
Ascensia launches Senseonics’ next-gen 180-day Eversense E3 CGM in U.S.
Ascensia Diabetes Care announced today that it launched the Senseonics (NYSE:SENS) Eversense E3 system in the U.S. The next-generation Eversense E3 continuous glucose monitoring (CGM) system, developed by Germantown, Maryland-based Senseonics, received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S. Get the full story […]
Diabetes tech is off to a hot start in 2022
Diabetes technology developers have high hopes for the year ahead, some of which have already come to fruition. Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes. […]
Senseonics up on Q4 earnings beat, upcoming U.S. launch of Eversense E3
Senseonics (NYSE:SENS) shares are up today on Q4 earnings ahead of the consensus forecast, with the company planning to launch its next-gen, implantable, 6-month CGM in the U.S next month. The Germantown, Maryland-based company posted revenues of $4 million for the three months ended Dec. 31, 2021, representing sales growth of 2.6% from the same […]
Ascensia launches Senseonics’ remote monitoring app for Android devices in Europe
Ascensia Diabetes Care announced today that it launched Senseonics‘ (NYSE:SENS) Eversense NOW remote monitoring app for Androids in Europe. The launch makes remote monitoring capabilities available for all of Senseonics Eversense and Eversense XL continuous glucose monitoring (CGM) users on Android and iOS operating systems in the U.S. and Europe, respectively. Get the full story at our […]
Senseonics wins FDA approval for next-generation Eversense 180-day CGM, provides 2022 outlook
Senseonics (NYSE:SENS) announced today that the FDA approved its next-generation continuous glucose monitor system, which lasts up to half a year. Germantown, Maryland–based Senseonics designed the Eversense E3, which includes proprietary sacrificial boronic acid (SBA) technology, to extend longevity to six months (180 days). Senseonics previously offered the system with a 90-day wear time. Data […]
With FDA clearance ‘imminent’ for Senseonics 180-day CGM, what’s next?
When Dr. Fran Kaufman began her career in the late 1970s, diabetes management consisted of urine testing and animal insulin. At that point, it had not been proven that managing glucose actually mattered, according to Kaufman, and proof didn’t come until 1992 with the conclusion of the DCCT study. “I’ve seen a lot of innovation,” […]
Senseonics expects FDA approval for next-gen 180-day CGM in ‘coming weeks’
Senseonics (NYSE:SENS) announced that it anticipates the FDA to decide within weeks on approval of its new CGM system. The company seeks a premarket approval supplement for the next-generation Eversense 180-day implantable continuous glucose monitoring (CGM) system. Data presented earlier this year demonstrated strong accuracy. The next-generation Eversense matched performance levels compared to the current […]
